HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paolo M Comoglio Selected Research

Colorectal Neoplasms (Colorectal Cancer)

1/2018A Molecularly Annotated Model of Patient-Derived Colon Cancer Stem-Like Cells to Assess Genetic and Nongenetic Mechanisms of Resistance to Anti-EGFR Therapy.
6/2017Stroma-derived HGF drives metabolic adaptation of colorectal cancer to angiogenesis inhibitors.
6/2016Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
1/2016Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.
1/2015IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies.
7/2014MET-mediated resistance to EGFR inhibitors: an old liaison rooted in colorectal cancer stem cells.
3/2014MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
5/2012Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
11/2011A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
5/2011Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paolo M Comoglio Research Topics

Disease

73Neoplasms (Cancer)
05/2022 - 12/2002
21Neoplasm Metastasis (Metastasis)
01/2021 - 12/2002
17Carcinoma (Carcinomatosis)
10/2022 - 03/2002
10Colorectal Neoplasms (Colorectal Cancer)
01/2018 - 05/2011
5Pancreatic Neoplasms (Pancreatic Cancer)
01/2021 - 07/2004
4Lung Neoplasms (Lung Cancer)
01/2016 - 05/2013
4Carcinogenesis
08/2010 - 08/2003
3Glioblastoma (Glioblastoma Multiforme)
01/2021 - 09/2012
3Oncogene Addiction
01/2018 - 06/2008
3Hypoxia (Hypoxemia)
06/2017 - 01/2006
3Stomach Neoplasms (Stomach Cancer)
09/2013 - 10/2008
2Adenocarcinoma
12/2018 - 08/2009
2Colonic Neoplasms (Colon Cancer)
01/2018 - 02/2012
2Disease Progression
06/2016 - 05/2012
2Pathologic Processes
12/2014 - 11/2004
2Breast Neoplasms (Breast Cancer)
01/2010 - 03/2002
2Melanoma (Melanoma, Malignant)
08/2009 - 12/2008
2Ovarian Neoplasms (Ovarian Cancer)
06/2006 - 03/2004
1Brain Neoplasms (Brain Tumor)
01/2021
1Triple Negative Breast Neoplasms
12/2018
1Starvation
06/2017
1Fatigue
06/2016
1Exanthema (Rash)
06/2016
1Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
01/2016
1Rectal Neoplasms (Rectal Cancer)
11/2015
1Inflammation (Inflammations)
02/2015
1Multiple Myeloma
03/2014
1Ataxia Telangiectasia (Louis Bar Syndrome)
04/2011
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2011
1Wounds and Injuries (Trauma)
12/2010

Drug/Important Bio-Agent (IBA)

20Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
12/2018 - 04/2003
17Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
03/2022 - 08/2003
15Phosphotransferases (Kinase)IBA
10/2022 - 12/2002
11LigandsIBA
01/2021 - 08/2003
9Proteins (Proteins, Gene)FDA Link
12/2018 - 03/2002
8Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
03/2015 - 12/2002
8Proto-Oncogene Proteins c-metIBA
12/2014 - 08/2003
6Pharmaceutical PreparationsIBA
01/2016 - 03/2004
5Biological ProductsIBA
01/2021 - 03/2006
5ErbB Receptors (EGF Receptor)IBA
01/2015 - 07/2004
4Cetuximab (Erbitux)FDA Link
01/2018 - 11/2011
4Monoclonal AntibodiesIBA
12/2014 - 10/2008
4Tyrosine (L-Tyrosine)FDA Link
04/2011 - 07/2004
3Messenger RNA (mRNA)IBA
12/2018 - 08/2004
3CytokinesIBA
01/2016 - 11/2010
3Biomarkers (Surrogate Marker)IBA
01/2015 - 11/2011
3AntibodiesIBA
03/2014 - 11/2008
3tyrosine receptor (receptor, tyrosine)IBA
09/2013 - 01/2009
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
09/2012 - 03/2004
3Small Interfering RNA (siRNA)IBA
04/2011 - 05/2006
3IntegrinsIBA
12/2010 - 06/2005
3Semaphorins (Semaphorin)IBA
08/2009 - 04/2004
24-hexyloxyaniline (HOA)IBA
05/2022 - 03/2022
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2021 - 05/2012
2Oncogene Proteins (Oncogene Protein)IBA
10/2018 - 11/2011
2AntagomirsIBA
02/2012 - 12/2008
2plexinIBA
08/2010 - 08/2009
2Cisplatin (Platino)FDA LinkGeneric
06/2006 - 03/2004
2Paclitaxel (Taxol)FDA LinkGeneric
06/2006 - 03/2004
2Epidermal Growth Factor (EGF)IBA
07/2004 - 03/2004
1InterferonsIBA
01/2019
1methionylmethionine (Met-Met)IBA
12/2018
1Glucose (Dextrose)FDA LinkGeneric
06/2017
1Angiogenesis InhibitorsIBA
06/2017
1A-Form DNA (A-DNA)IBA
10/2016
1Lapatinib (GW572016)FDA Link
06/2016
1Trastuzumab (Herceptin)FDA Link
06/2016
1Panitumumab (Vectibix)FDA Link
06/2016
1BilirubinIBA
06/2016
1Codon (Codons)IBA
06/2016
1TankyrasesIBA
01/2016
1CrizotinibIBA
03/2015
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2015
1Neutralizing AntibodiesIBA
11/2014
1ficlatuzumabIBA
11/2014
1Immunoglobulin Fab FragmentsIBA
01/2014
1Doxycycline (Periostat)FDA LinkGeneric
01/2014
1Bevacizumab (Avastin)FDA Link
09/2013
13- ((3- ((4- (4- morpholinylmethyl)- 1H- pyrrol- 2- yl)methylene)- 2- oxo- 2,3- dihydro- 1H- indol- 5- yl)methyl)- 1,3- thiazolidine- 2,4- dioneIBA
09/2013
1dactolisibIBA
05/2012
1AZD 6244IBA
05/2012
1NF-kappa B (NF-kB)IBA
04/2011
1ChromatinIBA
04/2011
1Transcription Factors (Transcription Factor)IBA
04/2011
1RNA (Ribonucleic Acid)IBA
04/2011
1DNA (Deoxyribonucleic Acid)IBA
01/2011
1TetraspaninsIBA
12/2010
1EpitopesIBA
08/2010
1src-Family KinasesIBA
08/2010

Therapy/Procedure

33Therapeutics
03/2022 - 03/2002
3Radiotherapy
01/2016 - 07/2004
2Transplantation
01/2021 - 10/2018
2Precision Medicine
12/2018 - 11/2011
2Immunotherapy
01/2014 - 11/2008
2Heterologous Transplantation (Xenotransplantation)
08/2010 - 04/2009
2Drug Therapy (Chemotherapy)
06/2006 - 03/2004
1Aftercare (After-Treatment)
03/2022
1Subcutaneous Injections
01/2021
1Chemoradiotherapy
11/2017
1Oral Administration
09/2013